Johnson & Johnson (JNJ)
Johnson & Johnson Stock Could Be Waking Up
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech segments show promising pipeline developments, with MedTech's growth and robotics ambitions offering future upside. Despite a dip in free cash flow, J&J's dividend remains attractive, with a solid 3.18% yield and a 62-year growth streak, supporting shareholder returns.
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Build Stability and Income With 3 Overlooked Dividend Leaders
Dividend investing is one of the most popular strategies among retail investors seeking a combination of stability and passive income. A long-term buy-and-hold approach for stalwart dividend players like The Coca-Cola Co. NYSE: KO or Johnson & Johnson NYSE: JNJ rewards patience and a commitment to reinvesting payouts over time.
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
Johnson & Johnson: The Worst Is Baked In
J&J's diversified business, robust pipeline, and strong free cash flow provide stability despite ongoing legal overhang from talcum powder claims. Legal risks remain a near-term headwind, but I believe any settlement will be manageable for J&J's financial strength and present a buying opportunity. J&J's 63-year dividend growth streak, solid payout ratio, and AAA credit rating make it an attractive choice for long-term, income-focused investors.
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
JNJ's Stock Price Is Back in Rally Mode—The Time to Buy Is Now
After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson's NYSE: JNJ stock price is back in rally mode. It is still early in the game, but the Q2 results affirm that growth is back, acceleration is happening and is expected to continue in the back half of the year.
